The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
All News
Article
Article
Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and their families, but also lead to wider economic and social burden.
Article
The ACR meeting is the premier educational event in rheumatology every year; it’s big for clinicians, academics, North American and international rheumatologists and those who will be presenting their research for the first time.
Your objectives in attending the annual meeting are:
No significant difference in effectiveness/treatment survival of different TNFi in axSpA
Failure of 1st TNFi did not diminish effectiveness of a second TNFi
Abs#938
#ACR21 @RheumNow
https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6
#ACR21 #Abstr0686 A study used PET-CT to initially rule out cancer. Interestingly, they found ⬆️median muscle FDG uptake with PET-CT in IIM vs Non-IIM. Need further study on its added value compared to MRI/EMG @RheumNow https://t.co/F0B86ygjI9 https://t.co/eiJnqpU8ft
Dr. P Crow #PhilipHenchLecture
IFN signature can parallel or predict flares #ACR21 @rheumnow https://t.co/OskxDuKPDH
Akhil Sood MD
Tweet
Abstr 0579
Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent
- Females & GC use more likely to switch agent
- Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch
#ACR21 @RheumNow https://t.co/FM5mSWmSNA
Richard Conway
Tweet
@zach_wallace_md on RTX vs CYC remission induction in AAV. Multivariable and propensity score matching. No difference in ESRD or mortality. Real world confirmation of RAVE. Abstr#954 #ACR21 @RheumNow https://t.co/oSauqV8JnD
Abst0944 #ACR21 #ACRBest @RheumNow microbiom evaluation of MZ twins discordant for PSO reveals Ruminococcus bromii species significantly reduced & two pathways related to tetrahydrofolate biosynthesis upregulated in PSO twins compared to their unaffected siblings (p< 0.05) https://t.co/67ao0l23sI
Eric Dein
Tweet
#ACR21 Clinical Pearl: Beware of low cholesterol!
Systemic inflammation can lower cholesterol levels! High inflammation and low cholesterol may INCREASE, not decrease risk of CVD!
This is the "lipid paradox"
@Rheumnow https://t.co/dK7hD8zkVP
Pedro Castillo
Tweet
Soluble urinary ALCAM previously shown as potential biomarker for LN. Further study showing urinary ALCAM trended with changes in renal-SLEDAI and UPCr.
#ACR21 Abst#3053 @RheumNow https://t.co/IqVJej7yda
Abst 0947 #ACR21 @RheumNow KikGR x TNFDARE/+ mice study assessed contribution of gut-derived T cells to increased joint inflammation through production of pro-inflammatory cytokines like IL-17 and TNF. Photolabeled gut-trafficked T cells are observed in the Achilles enthesis
Bella Mehta
Tweet
Important to discuss men with #lupus
Nationwide claims study showed increased occurrence of multimorbidity in men with SLE compared to women with SLE #ACR21 @RheumNow @AliDuarteMD Abst#0579 #ACRBest https://t.co/ljflGU84Ro
No evidence to show increased risk of incident hypertension w/ TNFi use, after accounting for baseline & time-dependent confounding factors, in prospective AS cohort. Abs 0910 #ACR21 #RheumNow @RheumNow https://t.co/1SpQ51ftlK
Ear dyspigmentation, scalp dyspigmentation and scarring alopecia found more frequently in Black DLE pts. Findings may help assist in dx and tx plans. Abs 0598 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/a1pxWHJ7b5
David Liew
Tweet
Does AAV induction choice (CYC v RTX) affect long-term outcomes (that might be missed in clinical trials)?
Boston data done two ways: multivar analysis & trial emulation using PS
CYC and RTX-based induction both perform equally well over many years👍
#ACR21 ABST0954 @RheumNow https://t.co/8BZRgKiQNB
Richard Conway
Tweet
Dr Strand presents HRQoL measures for avacopan from ADVOCATE trial. Better HRQoL outcomes with avacopan. Great to have PRO data. Abstr#0955 #ACR21 @RheumNow https://t.co/9qBAHETX7s
French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4
Richard Conway
Tweet
@rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL
Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop


